SHC Stock Cash Flow Statements

Sotera Health Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Sotera Health Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31

operating activities:
net income	7,962,000	-13,260,000	12,323,000	16,998,000	8,754,000	6,323,000	38,681,000	-13,660,000	23,513,000	2,842,000	86,149,000	61,059,000	30,641,000	35,997,000	27,444,000	42,615,000	11,065,000
adjustments to reconcile net income to net cash from operating activities:
depreciation	23,093,000	22,130,000	20,672,000	23,207,000	20,075,000	20,306,000	20,664,000	17,993,000	18,989,000	18,931,000	47,496,000	31,611,000	15,867,000	16,703,000	16,395,000	15,683,000	15,379,000
amortization of intangible assets	11,923,000	18,674,000	19,640,000	19,858,000	19,755,000	20,124,000	20,058,000	20,182,000	20,501,000	20,607,000	61,596,000	41,378,000	20,182,000	21,443,000	21,239,000	21,778,000	22,282,000
loss on refinancing of debt			8,000	70,000
deferred income taxes	-9,024,000	-16,075,000	7,542,000	9,990,000	-4,658,000	-3,441,000	165,000	2,969,000	2,085,000	-1,770,000	17,153,000	10,416,000	5,633,000	-11,847,000	4,627,000	7,141,000	-3,637,000
share-based compensation expense	8,119,000	7,242,000	8,144,000	9,789,000	10,181,000	8,663,000	8,204,000	8,373,000	8,373,000	7,288,000	14,955,000	10,339,000	4,538,000		3,547,000	3,493,000	3,449,000
accretion of asset retirement obligations	562,000	574,000	723,000	637,000	636,000	642,000	730,000	556,000	555,000	572,000	1,645,000	1,118,000	520,000	501,000	598,000	602,000	551,000
unrealized foreign exchange gain	13,527,000	5,359,000
unrealized (gain) loss on derivatives not designated as hedging instruments
amortization of debt issuance costs	1,375,000	1,270,000	1,280,000	1,254,000	2,169,000	2,535,000	2,529,000	2,410,000	2,202,000	1,910,000	4,259,000	2,836,000	1,414,000	1,372,000	1,544,000	1,582,000	1,663,000
other	-1,006,000	-1,468,000	-1,092,000	-1,017,000	-2,260,000	-998,000	-1,827,000	-869,000	-1,295,000	-1,328,000	-6,109,000	-4,043,000	-1,989,000	-6,554,000	-1,933,000	-1,398,000	-2,843,000
changes in operating assets and liabilities:
accounts receivable	-4,546,000	13,630,000	-14,026,000	-6,019,000	-18,308,000	40,569,000	-22,026,000	-2,247,000	-7,674,000	10,223,000	-8,558,000	-13,921,000	-6,387,000	-10,608,000	20,853,000	-21,620,000	-4,134,000
inventories	4,176,000	-11,839,000	1,470,000	4,861,000	-7,032,000	-4,052,000	-9,106,000	3,011,000	5,635,000	-9,512,000	13,896,000	14,012,000	9,323,000	-16,816,000	-2,659,000	-1,869,000	1,099,000
other current assets	-10,557,000	-3,693,000	6,891,000	309,000	-3,352,000	-250,000	4,895,000	8,328,000	-2,902,000	-6,318,000	-13,066,000	-6,683,000	-8,934,000	-5,777,000	1,242,000	3,307,000	-2,324,000
accounts payable	-6,098,000	11,671,000	-7,528,000	2,843,000	5,321,000	-7,280,000	12,079,000	2,913,000	-10,715,000	-9,610,000	-13,367,000	-9,993,000	-12,742,000	20,052,000	-15,371,000	8,455,000	6,625,000
accrued liabilities	-4,345,000	-10,169,000	10,132,000	15,567,000	12,421,000	-31,006,000	14,889,000	-33,662,000	13,447,000	8,826,000	-1,874,000	-11,869,000	2,479,000	9,581,000	-3,610,000	1,167,000	-5,542,000
illinois eo litigation settlements
georgia eo litigation settlement			0	0	0	-35,000,000	0
income taxes payable / receivable	-7,656,000	-556,000	5,724,000	1,089,000	-3,535,000	-1,808,000	19,290,000	-4,299,000	-4,516,000	-9,551,000	-25,050,000	-15,968,000	-5,222,000	13,723,000	378,000	520,000	-4,518,000
other liabilities	-98,000	71,000	-3,485,000	-180,000	48,000	-176,000	-924,000	-297,000	-140,000	-372,000	1,489,000	-468,000	-81,000	-79,000	-195,000	-1,608,000	1,513,000
other long-term assets	-473,000	-587,000	-1,756,000	-1,854,000	-1,008,000	-2,224,000	3,933,000	-4,529,000	254,000	104,000	-4,259,000	-4,426,000	-341,000	-4,027,000	-334,000	267,000	-282,000
net cash from operating activities	57,416,000	55,521,000	55,717,000	97,453,000	61,295,000	9,699,000	113,123,000	41,849,000	-336,575,000	33,871,000	176,035,000	108,256,000	49,967,000	66,351,000	80,938,000	78,097,000	56,159,000
capex	-33,964,000	-6,876,000	-72,062,000	-33,555,000	-43,837,000	-19,436,000	-64,489,000	-52,618,000	-49,209,000	-31,939,000	-92,059,000	-53,719,000	-35,546,000	-41,264,000	-16,109,000	-23,847,000	-20,942,000
free cash flows	23,452,000	48,645,000	-16,345,000	63,898,000	17,458,000	-9,737,000	48,634,000	-10,769,000	-385,784,000	1,932,000	83,976,000	54,537,000	14,421,000	25,087,000	64,829,000	54,250,000	35,217,000
investing activities:
purchases of property, plant and equipment	-31,229,000	-19,918,000	-65,870,000	-36,389,000	-41,921,000	-34,890,000	-64,826,000	-52,015,000	-53,134,000	-45,000,000	-110,642,000	-71,642,000	-35,546,000	-41,264,000	-16,109,000	-23,847,000	-20,942,000
other investing activities	0	37,000	0	37,000	0	37,000	0	37,000	0	32,000	34,000			16,000
net cash from investing activities	-31,229,000	-19,881,000	-65,870,000	-36,352,000	-41,921,000	-34,853,000	-64,826,000	-51,978,000	-53,134,000	-44,968,000	-110,158,000	-71,192,000	-35,483,000	-72,263,000	-16,596,000	-24,455,000	-46,519,000
financing activities:
proceeds from long-term borrowings				0				0	0	500,000,000
payments of debt issuance costs and debt discount			-17,000	-1,850,000				-973,000
payment on long-term borrowings	-3,774,000	-3,773,000			-2,259,350,000	-1,250,000
buyout of leased facility			0	0
shares withheld for employee taxes on equity awards	-54,000	-3,600,000
other financing activities	-789,000	-704,000	1,670,000	-804,000	-508,000	-2,664,000	1,546,000	-1,231,000	-495,000	-1,627,000	-1,452,000	-1,056,000	-418,000
net cash from financing activities	-6,933,000	-8,087,000	-6,548,000	-2,654,000	-29,421,000	-11,941,000	-3,793,000	-3,454,000	-710,000	273,916,000	-1,483,000	-1,083,000	-449,000	-1,782,000	-103,414,000	-8,307,000	-3,783,000
effect of exchange rate changes on cash and cash equivalents	8,937,000	-337,000	-12,916,000	2,277,000	-5,015,000	-1,739,000	4,616,000	-4,373,000	729,000	1,067,000	-6,357,000	-2,287,000	487,000	-301,000	-2,233,000	2,873,000	-295,000
net increase in cash and cash equivalents, including restricted cash	28,191,000	27,216,000	-29,617,000			-38,834,000	49,120,000	-17,956,000	-389,690,000	263,886,000	58,037,000	33,694,000	14,522,000	-7,995,000	-41,305,000	48,208,000	5,562,000
cash and cash equivalents, including restricted cash, at beginning of period	0	278,865,000	0	0	0	301,654,000	0	0	0	396,294,000	106,924,000	106,924,000	106,924,000	0	0	0	102,454,000
cash and cash equivalents, including restricted cash, at end of period	28,191,000	306,081,000	-29,617,000	60,724,000	-15,062,000	262,820,000	49,120,000	-17,956,000	-389,690,000	660,180,000	164,961,000	140,618,000	121,446,000	-7,995,000	-41,305,000	48,208,000	108,016,000
supplemental disclosures of cash flow information:
cash paid during the period for interest	55,300,000	47,416,000	37,145,000	31,610,000	41,434,000	69,735,000	23,146,000	72,344,000	42,896,000	35,456,000	65,045,000	42,057,000	15,809,000	5,046,000	17,111,000	16,870,000	19,745,000
cash paid during the period for income taxes, net of tax refunds received	19,992,000	12,215,000	23,382,000	14,733,000	17,877,000	9,837,000	7,623,000	14,997,000	13,576,000	14,014,000	56,474,000	37,340,000	13,505,000	20,085,000	9,137,000	11,224,000	11,561,000
purchases of property, plant and equipment included in accounts payable	-2,735,000	13,042,000	-6,192,000	2,834,000	-1,916,000	15,454,000	337,000	-603,000	3,925,000	13,061,000	18,583,000	17,923,000
unrealized loss on derivatives not designated as hedging instruments		1,604,000				1,833,000
illinois eo litigation settlement		30,943,000					0	0
payments of debt issuance costs		-10,000				-1,291,000				-24,457,000		-27,000	-31,000			-226,000	-3,435,000
buyout of leased facilities						-6,736,000
impairment of investment in unconsolidated affiliate											9,613,000	9,613,000
unrealized foreign exchange (gain) loss			-12,582,000			-5,061,000					-5,610,000
unrealized gain on derivatives not designated as hedging instruments							-2,724,000			227,000	-4,323,000		-7,364,000
purchase of regulatory compliance associates inc., net of cash acquired
proceeds from revolving credit facility and long-term borrowings
payment of revolving credit facility							0	0
payments of long-term borrowings
payment of long-term borrowings
unrealized foreign exchange (gains) losses
net decrease in cash and cash equivalents, including restricted cash
payment on revolving credit facility										-200,000,000
loss on extinguishment of debt														4,000	6,365,000	0	14,312,000
purchase of bioscience laboratories, llc, net of cash acquired														0	230,000	-608,000	-13,152,000
purchase of mandatorily redeemable noncontrolling interest in nelson laboratories fairfield, inc.														0	0	0	-12,425,000
purchase of noncontrolling interests in china subsidiaries														0	-698,000
payments of debt issuance costs and prepayment premium											-31,000			-74,000
balance at january 1, 2021
acquisition of noncontrolling interests
issuance of shares
share-based compensation plans											-789,000	-28,000
comprehensive income
pension and post-retirement plan adjustments, net of tax
foreign currency translation
interest rate derivatives, net of tax
balance at december 31, 2021
balance at december 31, 2022
balance at december 31, 2023
adjustment to purchase of regulatory compliance associates inc.											450,000	450,000	63,000
unrealized foreign exchange losses												1,274,000	2,430,000
unrealized gains on derivatives not designated as hedging instruments												-8,029,000
unrealized foreign exchange loss										802,000
purchase of iotron industries canada, inc., net of cash acquired
proceeds from issuance of common stock, net of underwriting discounts and issuance costs
repurchase of common shares
payments on revolving credit facility and long-term borrowings
balance at january 1, 2020
repurchase of shares
balance at december 31, 2020
payments on debt
balance at june 30, 2022											282,902,000	282,902,000
balance at september 30, 2022											282,113,000
balance at march 31, 2022												282,930,000
equipment purchases included in accounts payable													9,508,000	-3,000	4,857,000	2,281,000	7,389,000
impairment of long-lived assets
share-based non-cash compensation expense
unrealized foreign exchange (gains) / losses																	2,354,000
unrealized gain on embedded derivative instruments
dividends and distributions to shareholders
balance at january 1, 2019
cumulative-effect adjustment upon adoption of asu 2014-09
interest rate swaps
balance at december 31, 2019
unrealized foreign exchange losses /															-382,000
unrealized (gain) / loss on embedded derivative instruments															1,190,000	-761,000	-853,000
proceeds from borrowings
proceeds from revolving credit facility
payments on long-term borrowings
gain on interest rate swap
net cash from (provided by) financing activities

We provide you with 20 years of cash flow statements for Sotera Health stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sotera Health stock. Explore the full financial landscape of Sotera Health stock with our expertly curated income statements.

The information provided in this report about Sotera Health stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.